Physician
Bryson Cancer Care INC
Bryson Cancer Care INC was paid $3.24M by Medicaid between Jan 2018 and Nov 2024, across 40 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 25% of everything it billed.
33Billing provider infoBRYSON CANCER CARE INC
VISALIA, CA 93291
VISALIA, CA 93291
33aNPI1508883257assigned 07/17/2006
33bProvider typeHematology & Oncology Physician
28Total paid$3.24M
24GClaims60,735
24DCodes billed40
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in California
Rank by total paid#7 of 180
Median peer was paid$26K
This provider vs. median126×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,262 | $528K | |
| 2019 | 11,524 | $407K | |
| 2020 | 7,454 | $308K | |
| 2021 | 6,417 | $361K | |
| 2022 | 8,501 | $221K | |
| 2023 | 8,574 | $266K | |
| 2024incomplete | 7,003 | $1.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 25% | 140 | 108 | $815K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 18% | 4,527 | 2,570 | $596K |
| J0897 | Injection, denosumab, 1 mg | 9.5% | 417 | 391 | $306K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 8.2% | 171 | 102 | $267K |
| 96367 | 5.4% | 3,655 | 2,176 | $174K | |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 5.1% | 179 | 115 | $166K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.8% | 6,561 | 5,587 | $154K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.0% | 6,698 | 3,634 | $130K |
| J2505 | Injection, pegfilgrastim, 6 mg | 3.8% | 219 | 140 | $123K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.0% | 5,023 | 2,859 | $96K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1.9% | 4,700 | 2,348 | $60K |
| J7050 | Infusion, normal saline solution, 250 cc | 1.7% | 5,835 | 3,530 | $56K |
28 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 1.7% | 1,720 | $54K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 386 | $51K |
| J1453 | Injection, fosaprepitant, 1 mg | 1.4% | 1,792 | $44K |
| 96417 | <1% | 2,193 | $22K | |
| 96368 | <1% | 1,579 | $22K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,248 | $21K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 33 | $18K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 766 | $10K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,994 | $7K |
| 96415 | <1% | 1,044 | $7K | |
| 96411 | <1% | 1,124 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 423 | $6K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 371 | $5K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 75 | $4K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 535 | $3K |
| 96416 | <1% | 111 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 594 | $2K |
| J0641 | Injection, levoleucovorin, not otherwise specified, 0.5 mg | <1% | 150 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 830 | $1K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 76 | $1K |
| 80053 | Comprehensive metabolic panel | <1% | 417 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,835 | $1K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 15 | $372.78 |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 43 | $370.72 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 71 | $174.72 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 130 | $69.81 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17 | $54.02 |
| 83735 | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRYSON, DAVID (CEO)